Director/PDMR Shareholding (2543D)
March 18 2011 - 12:05PM
UK Regulatory
TIDMHIK
RNS Number : 2543D
Hikma Pharmaceuticals Plc
18 March 2011
Hikma Pharmaceuticals PLC - LTIP Awards
LONDON, 18 March 2011: Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) announces that the Remuneration Committee has made the
following nil-cost awards under the Hikma Pharmaceuticals PLC 2005
Long-Term Incentive Plan (the "LTIP") to Persons Discharging
Managerial Responsibility ("PDMR") of the Company.
Awards under the LTIP were made on 18 March 2011 at a price of
GBP7.23p per ordinary share as follows:-
Name of Director/PDMR Number of LTIP Shares
Bassam Kanaan 50,400
Michael Raya 45,200
Khalid Nabilsi 37,000
Majda Labadi 25,800
The shares subject to the LTIP awards will only be released to
the participants in three years time, subject to their continued
employment and the satisfaction of the comparative Total
Shareholder Return ("TSR"), sales growth, earnings per share
("EPS") growth and return on invested capital ("ROIC") performance
targets. Half of the award is subject to TSR against the Comparator
Group and requires at least upper quartile performance to vest in
full. The remaining half is split equally between the financial
targets and requires sales growth of 13%, EPS growth of 20% and
ROIC of 12% to vest in full. Each target is measured individually
and is independent of the other targets.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles +44 20 7399 2760
Company Secretary
Susan Ringdal +44 20 7399 2770
Investor Relations Director
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three
businesses: "Branded", "Injectables" and "Generics". Hikma's
operations are based principally in the Middle East and North
Africa ("MENA") region, where it is a market leader and sells
across 17 countries, the United States and Europe. In 2010, the
Group achieved revenues of $731 million (2009 $637 million) and
profit attributable to shareholders was $99 million (2009 $78
million). For news and other information, please visit
www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBLGDXSGBBGBI
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024